2022
Breast Cancer Screening: Is There Room for De-escalation?
Kim L, Lannin D. Breast Cancer Screening: Is There Room for De-escalation? Current Breast Cancer Reports 2022, 14: 153-161. PMID: 36404936, PMCID: PMC9640864, DOI: 10.1007/s12609-022-00465-z.Peer-Reviewed Original Research
2018
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.Peer-Reviewed Original Research
2017
Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer
Chagpar AB, Hatzis C, Pusztai L, DiGiovanna MP, Moran M, Mougalian S, Sanft T, Evans S, Hofstatter E, Wilson LD, Lannin DR. Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer. Annals Of Surgical Oncology 2017, 24: 3073-3081. PMID: 28766195, DOI: 10.1245/s10434-017-5936-x.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalLN evaluationPositive breast cancerOverall survivalBreast cancerHormone receptor-positive breast cancerWomen Aged 70 YearsReceptor-positive breast cancerLymph node evaluationCancer-specific survivalLower hazard rateLN surgeryBetter OSPatient ageSEER databasePatient selectionTumor characteristicsSEER dataPatientsNode evaluationHormone receptorsCancerSurvivalTreatment variablesNCDBAre Small Breast Cancers Good because They Are Small or Small because They Are Good?
Lannin DR, Wang S. Are Small Breast Cancers Good because They Are Small or Small because They Are Good? New England Journal Of Medicine 2017, 376: 2286-91. PMID: 28591529, DOI: 10.1056/nejmsr1613680.Peer-Reviewed Original Research
2015
Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011
Killelea B, Chagpar A, Horowitz N, Lannin D. Characteristics and treatment of Her2 positive breast cancer: 43,485 cases from the National Cancer Database (NCDB) treated in 2010 and 2011. Journal Of The American College Of Surgeons 2015, 221: e4. DOI: 10.1016/j.jamcollsurg.2015.08.310.Peer-Reviewed Original ResearchReview of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH).
Gnanajothy R, Chung G, DiGiovanna M, Abu-Khalaf M, Lannin D, Harris L. Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH). Journal Of Clinical Oncology 2015, 33: 144-144. DOI: 10.1200/jco.2015.33.28_suppl.144.Peer-Reviewed Original Research
2014
Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer.
Brown J, Bai Y, Bossuyt V, Nixon C, Lannin D, Rimm D. Quantitative assessment of CD3, CD8, and CD20 in tumor-infiltrating lymphocytes and predictive value for response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2014, 32: 1027-1027. DOI: 10.1200/jco.2014.32.15_suppl.1027.Peer-Reviewed Original Research
2013
Triple-negative breast cancer: molecular characterization and targeted therapies
Nicholson A, Bishop J, Lannin D, Killelea B, Guo X, Cha C, Dixon J. Triple-negative breast cancer: molecular characterization and targeted therapies. Breast Cancer Management 2013, 2: 417-430. DOI: 10.2217/bmt.13.40.Peer-Reviewed Original ResearchBreast cancerTriple-negative breast cancerAggressive breast cancerCancer Genome Atlas NetworkAggressive subtypeSingle therapyClinical trialsTherapeutic targetExtensive molecular characterizationMolecular alterationsIndividual cancersCancerTherapyMolecular targetsMolecular reviewMolecular characterizationRelated mutationsSubtypesTrials
2012
Accuracy of breast MRI in predicting pathologic tumor size.
Caprio K, Chagpar A, Hooley R, Tavassoli F, Honarpishe H, Lannin D, Killelea B, Horowitz N. Accuracy of breast MRI in predicting pathologic tumor size. Journal Of Clinical Oncology 2012, 30: 1109-1109. DOI: 10.1200/jco.2012.30.15_suppl.1109.Peer-Reviewed Original ResearchPathologic tumor sizeTumor sizeAccuracy of MRIMRI sizePathologic sizePathology sizeBreast cancerMRI lesion sizeSitu breast cancerPreoperative planning toolFinal pathologyNeoadjuvant chemotherapyPatient agePathologic findingsTumor histologyPreoperative MRILesion sizeLesionsBreast MRISpearman's rho coefficientPatientsMRICancerModest correlationSpearman coefficientSurgical Intervention Following Neoadjuvant Chemotherapy in Breast Cancer
Sowden M, Grube B, Killilea B, Lannin D. Surgical Intervention Following Neoadjuvant Chemotherapy in Breast Cancer. 2012 DOI: 10.5772/24519.Peer-Reviewed Original Research
2009
Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology
Schwartz J, Christy C, Grube B, Rishi M, Tavassoli F, Bossuyt V, Harris L, DiGiovanna M, Lannin D. Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology. Journal Of Clinical Oncology 2009, 27: 633-633. DOI: 10.1200/jco.2009.27.15_suppl.633.Peer-Reviewed Original ResearchDuctal intraepithelial neoplasiaHistologic subtypeInvasive cancerHormone receptor negativePure invasive cancersInvasive breast cancerDifferent clinical behaviorDifferent histologic subtypesCribriform subtypeMicropapillary subtypeReceptor negativeIntraepithelial neoplasiaComedo subtypeClinical behaviorPapillary subtypeBreast centerBreast cancerLarge lesionsSubtypesCancerBiologic significanceHormone receptorsHistologic architectureBiological behaviorSignificant financial relationship
1998
Racial Differences in Breast Cancer in a Rural Population: Comparison of Cytologic Nuclear Grade, Other Prognostic Factors, and Outcomes for Tumors Diagnosed by Fine‐Needle Aspiration Biopsy
Thomas P, Raab S, Lannin D, Slagel D, Silverman J. Racial Differences in Breast Cancer in a Rural Population: Comparison of Cytologic Nuclear Grade, Other Prognostic Factors, and Outcomes for Tumors Diagnosed by Fine‐Needle Aspiration Biopsy. The Breast Journal 1998, 4: 104-111. DOI: 10.1046/j.1524-4741.1998.420104.x.Peer-Reviewed Original ResearchFine-needle aspiration biopsyAfrican American patientsPrognostic factorsUnfavorable prognostic factorBreast cancerAfrican American womenCaucasian patientsNuclear gradeAspiration biopsyCaucasian counterpartsFavorable prognostic factorBreast cancer experienceRacial differencesNeedle aspiration biopsyCytologic nuclear gradeTumor sizeHistologic gradeTumor featuresSurvival disadvantagePatientsTumor typesCancer experienceCancerSmall sample sizeCaucasians
1994
Coming to terms with advanced breast cancer: Black women's narratives from Eastern North Carolina
Mathews H, Lannin D, Mitchell J. Coming to terms with advanced breast cancer: Black women's narratives from Eastern North Carolina. Social Science & Medicine 1994, 38: 789-800. PMID: 8184330, DOI: 10.1016/0277-9536(94)90151-1.Peer-Reviewed Original Research
1991
Mammography and age: Are we targeting the wrong women? A community survey of women and physicians
Harris R, Fletcher S, Gonzalez J, Lannin D, Degnan D, Earp J, Clark R. Mammography and age: Are we targeting the wrong women? A community survey of women and physicians. Cancer 1991, 67: 2010-2014. PMID: 2004318, DOI: 10.1002/1097-0142(19910401)67:7<2010::aid-cncr2820670730>3.0.co;2-8.Peer-Reviewed Original Research